Study guide
3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
Key Takeaways Explain This Topic AI
The American College of Surgeons (ACS) ATLS classification categorizes hemorrhagic shock into Classes I through IV based on blood loss volume, heart rate, blood pressure, pulse pressure, urine output, and base deficit.
Damage Control Resuscitation (DCR) prioritizes permissive hypotension (target SBP 80–90 mmHg or MAP 50–60 mmHg) to prevent disrupting nascent clots, but this strategy is strictly contraindicated in traumatic brain injury (TBI), where target SBP must remain ≥100–110 mmHg.
Massive Transfusion Protocols (MTP) mandate a balanced 1:1:1 ratio of packed red blood cells, fresh frozen plasma, and platelets, which was shown in the PROPPR trial to achieve earlier hemostasis and significantly reduce 24-hour mortality from exsanguination.
Tranexamic acid (TXA; 1 g IV over 10 min followed by 1 g IV over 8 hours) significantly reduces all-cause mortality when administered within 3 hours of trauma injury (CRASH-2 trial); administration beyond 3 hours is associated with increased bleeding mortality.
Massive transfusion induces citrate toxicity that rapidly chelates serum ionized calcium; clinicians must administer 1–2 g IV calcium chloride (or 3 g calcium gluconate) for every 4 units of blood products to maintain ionized calcium >1.1–1.2 mmol/L.
Last updated: October 2026
- Hypovolemic & Hemorrhagic Shock Fluid Protocols
- Staging of Hemorrhagic Shock and Non-Hemorrhagic Hypovolemia
Hypovolemic shock results from a critical decrease in intravascular volume, leading to reduced venous return (preload), decreased stroke volume, diminished cardiac output, and inadequate end-organ perfusion. The American College of Surgeons (ACS) Advanced Trauma Life Support (ATLS) classifies hemorrhagic shock into four distinct classes based on physiological derangement in a standard 70 kg adult. The heart-rate and urine-output numbers below are the classic teaching values; the current ATLS manual describes trends (normal, increased, decreased) and adds base deficit and the need for blood products, so treat the numbers as approximations.
- Parameter Class I Class II Class III Class IV
- Blood Loss (mL) <750 mL 750–1,500 mL 1,500–2,000 mL >2,000 mL
- Blood Loss (% Blood Vol) <15% 15%–30% 30%–40% >40%
- Heart Rate (bpm) <100 100–120 120–140 >140
- Blood Pressure Normal Normal Decreased Severely Decreased
- Pulse Pressure Normal / Widened Decreased (Narrowed) Decreased Severely Decreased / Flat
- Respiratory Rate (/min) 14–20 20–30 30–40 >35
- Urine Output (mL/hr) >30 20–30 5–15 Negligible
- Mental Status Slightly anxious Mildly anxious Anxious, confused Confused, lethargic
- Base Deficit (mEq/L) 0 to −2 −2 to −6 −6 to −10 ≤ −10
- Initial Resuscitation Crystalloid Crystalloid ± Blood Blood Products + Crystalloid Immediate MTP (1:1:1)
Note
Narrowing of the pulse pressure (systolic minus diastolic blood pressure) is the earliest clinical hemodynamic sign of Class II shock. Circulating catecholamines increase systemic vascular resistance, selectively elevating diastolic blood pressure before systolic pressure falls.
Non-Hemorrhagic Hypovolemic Shock
Non-hemorrhagic volume loss stems from gastrointestinal fluid losses (severe vomiting, cholera, profuse secretory diarrhea), renal losses (osmotic diuresis, diabetic ketoacidosis, excessive loop diuretics), or massive cutaneous losses/third-spacing:
Severe Thermal Burns : Resuscitation is guided by the Consensus Parkland formula : 4 mL × actual body weight (kg) × % Total Body Surface Area (%TBSA) burned (2nd and 3rd degree burns only) administered over the first 24 hours. Half of the total volume is infused over the first 8 hours from the time of burn injury, and the remaining half over the subsequent 16 hours. Balanced crystalloids (Lactated Ringer's) are required; Normal Saline precipitates profound hyperchloremic acidosis during large-volume burn resuscitation.
Damage Control Resuscitation (DCR) and Permissive Hypotension
Damage Control Resuscitation (DCR) is a structured trauma resuscitation paradigm designed to restore perfusion while avoiding the iatrogenic complications of traditional high-volume crystalloid resuscitation.
Core Tenets of DCR
Immediate Hemorrhage Control : Direct pressure, tourniquets, pelvic binders, surgical exploration, or interventional radiology angioembolization.
Minimization of Crystalloids : Avoiding large-volume crystalloid infusions (crystalloid fluids dilute clotting factors, cool the patient, induce endothelial glycocalyx shedding, and cause abdominal compartment syndrome).
Permissive Hypotension : Maintaining systemic blood pressure below normal levels until surgical hemostasis is achieved.
Target Parameters : Systolic blood pressure 80–90 mmHg (or mean arterial pressure 50–60 mmHg ).
Physiological Rationale : Elevated hydrostatic pressure dislodges newly formed platelet-fibrin plugs ("popping the clot") and accelerates hemorrhage. Permissive hypotension preserves minimal vital organ perfusion while preventing clot disruption.
Caution
Strict Contraindication in Traumatic Brain Injury (TBI) : Permissive hypotension is absolutely contraindicated in patients with known or suspected severe TBI (Glasgow Coma Scale ≤8) or spinal cord injury. In brain injury, autoregulation of cerebral blood flow is abolished, and cerebral perfusion pressure (CPP = MAP - ICP) directly mirrors systemic blood pressure. A single episode of SBP <90 mmHg doubles trauma brain mortality. The Brain Trauma Foundation guidelines mandate maintaining SBP ≥100 mmHg (for patients 50–69 years) or SBP ≥110 mmHg (for patients 15–49 or ≥70 years) in TBI.
Massive Transfusion Protocol (MTP) and the PROPPR Trial
Massive transfusion is clinically defined as the transfusion of ≥10 units of packed red blood cells (PRBCs) within 24 hours , or the rapid replacement of >4 units of PRBCs within 1 hour in the presence of ongoing life-threatening hemorrhage.
Balanced 1:1:1 Transfusion Ratio
Rather than administering PRBCs alone followed by late clotting factor repletion, modern emergency resuscitation utilizes a fixed, pre-assembled ratio of blood products:
- 1 unit of Packed Red Blood Cells (PRBC)
- 1 unit of Fresh Frozen Plasma (FFP)
- 1 unit of Platelets (typically 1 apheresis unit or 6 pooled random-donor units per 6 PRBC units)
- Landmark Evidence: The PROPPR Trial
The PROPPR trial (Pragmatic Randomized Optimal Platelet and Plasma Ratios, JAMA 2015) randomized 680 severely bleeding trauma patients to a 1:1:1 ratio versus a 1:1:2 ratio.
The 1:1:1 group achieved anatomical hemostasis significantly faster (86% vs. 78%, p = 0.006).
The 1:1:1 group demonstrated a significant reduction in 24-hour mortality from exsanguination (9.2% vs. 14.6%, p = 0.03).
Although overall 30-day all-cause mortality did not reach statistical significance between groups, early balanced resuscitation halted fatal exsanguination without increasing pulmonary complications or thrombotic events.
Viscoelastic Testing in Trauma: TEG and ROTEM
Standard coagulation assays (PT/INR, aPTT) are performed on platelet-poor plasma at a standardized temperature (37°C), taking 45–60 minutes to process and failing to reflect in vivo platelet function, clot kinetics, or hyperfibrinolysis. Viscoelastic hemostatic assays —Thromboelastography ( TEG ) and Rotational Thromboelastometry ( ROTEM )—evaluate whole blood clot formation in real time within 10 to 15 minutes.
Viscoelastic Phase TEG Parameter (Normal) ROTEM Parameter (Normal) Coagulation Defect Targeted Pharmacotherapy / Product
Clot Initiation R-time (Reaction time: 5–10 min) CT (Clotting Time: 100–240 sec) Deficient clotting factors, severe hemodilution Fresh Frozen Plasma (FFP) (10–15 mL/kg) or 4-Factor PCC
Clot Kinetics / Propagation K-time (1–3 min); α-angle (53°–72°) CFT (Clot Formation Time: 70–150 s); α-angle (65°–79°) Deficient fibrinogen polymerization; weak thrombin burst Cryoprecipitate (10 units or 2 pooled units) or Fibrinogen concentrate
Clot Strength MA (Maximum Amplitude: 50–70 mm) MCF (Maximum Clot Firmness: 50–72 mm) Platelet hypofunction (80%) or low fibrinogen (20%) Platelets (1 apheresis pack) ± Cryoprecipitate (if α-angle low)
Clot Lysis (Fibrinolysis) LY30 (Clot lysis at 30 min: 0%–3%) ML (Maximum Lysis: <15%) Hyperfibrinolysis (accelerated plasmin breakdown) Tranexamic Acid (TXA) IV loading bolus & infusion
Tranexamic Acid (TXA) Resuscitation Protocols
Tranexamic acid is a synthetic lysine analogue that competitively inhibits the lysine-binding sites on plasminogen. By preventing plasminogen activation to plasmin, TXA halts plasmin-mediated fibrin degradation, stabilizing the hemostatic clot.
Dosing Regimen & Administration
Loading Dose : 1 g IV infused over 10 minutes (rapid push over <5 minutes can cause severe transient arterial hypotension due to histamine release).
Maintenance Infusion : 1 g IV infused continuously over 8 hours .
Evidence from the CRASH-2 Trial & The 3-Hour Time Window
The landmark CRASH-2 trial (Lancet 2010; n=20,211 adult trauma patients) demonstrated that TXA significantly reduced:
All-cause mortality (14.5% vs. 16.0%; relative risk [RR] 0.91; p = 0.0035).
Death due to bleeding (4.9% vs. 5.7%; RR 0.85; p = 0.0077).
Important
The 3-Hour Critical Rule : Subgroup analysis of CRASH-2 revealed that the efficacy of TXA is strictly time-dependent. When given within 1 hour of injury, TXA reduced the risk of death due to bleeding by 32% (RR 0.68). When administered between 1 and 3 hours, the risk reduction was 21% (RR 0.79).
However, when TXA was administered greater than 3 hours after injury , it was associated with a statistically significant increase in death due to bleeding (4.4% vs. 3.1%; RR 1.44; p = 0.004). Therefore, TXA must NOT be initiated if more than 3 hours have elapsed since the traumatic injury .
Citrate Toxicity, Calcium Repletion, and Halting the Lethal Triad
Stored packed red blood cells, fresh frozen plasma, and platelets contain sodium citrate as an anticoagulant preservative. Citrate prevents clotting during storage by chelating free calcium ions (Ca²⁺).
Citrate Toxicity and Acute Hypocalcemia
During rapid massive transfusion, the rate of citrate infusion exceeds the metabolic clearance capacity of the liver, particularly in patients who are hypothermic, acidotic, or experiencing hepatic hypoperfusion. Citrate accumulates and binds circulating ionized calcium, causing precipitous hypocalcemia .
Pathophysiological Consequences : Ionized calcium is an essential cofactor (Factor IV) in the assembly of the tenase and prothrombinase coagulation complexes. Severe hypocalcemia (iCa <1.0 mmol/L) induces refractory coagulopathy, impairs myocardial contractility, causes arterial vasodilation, prolongs the QTc interval, and triggers life-threatening dysrhythmias.
Emergency Calcium Repletion Protocol :
Target serum ionized calcium: >1.1–1.2 mmol/L .
Empiric Administration Rule : Administer 1 to 2 g IV Calcium Chloride (or 3 g IV Calcium Gluconate ) for every 4 units of blood products transfused .
Calcium Chloride vs. Gluconate : 1 g of calcium chloride provides 13.6 mEq (272 mg) of elemental calcium, while 1 g of calcium gluconate provides 4.65 mEq (93 mg), so roughly 3 g of gluconate equals 1 g of chloride. Both ionize rapidly; the old claim that gluconate needs hepatic metabolism is a myth. Chloride is usually given through central or large, well-running access because extravasation causes tissue necrosis; gluconate is the safer peripheral choice.
The Lethal Triad of Trauma
The vicious cycle of trauma mortality consists of hypothermia, coagulopathy, and acidosis .
Hypothermia (<35°C) : Slows the kinetics of coagulation enzyme cascades and inhibits platelet activation. Every 1°C drop in core temperature reduces coagulation enzyme activity by 10%. All transfused fluids and blood products must pass through high-flow commercial fluid warmers, and active external warming blankets must be deployed immediately.
Acidosis (pH <7.20, Base Deficit ≤ −6 mEq/L) : Inactivates coagulation factors; at pH <7.20, factor Xa/Va prothrombinase activity drops by over 50%. Acidosis is corrected by restoring microvascular perfusion through hemostasis and RBC oxygen delivery, not by pushing sodium bicarbonate boluses.
Coagulopathy : Dilutional coagulopathy is averted by initiating balanced 1:1:1 transfusion and replacing calcium aggressively.